Tesaro Inc. (NASDAQ:TSRO) – Equities researchers at FBR & Co raised their FY2019 earnings per share (EPS) estimates for Tesaro in a report released on Tuesday. FBR & Co analyst E. White now forecasts that the firm will post earnings of $2.39 per share for the year, up from their prior forecast of $1.36. FBR & Co currently has a “Outperform” rating and a $115.00 target price on the stock.
A number of other equities research analysts have also issued reports on the stock. Mizuho dropped their target price on shares of Tesaro from $100.00 to $94.00 and set a “buy” rating for the company in a report on Friday, August 5th. Lake Street Capital reaffirmed a “buy” rating and set a $114.00 target price on shares of Tesaro in a report on Tuesday, September 6th. Robert W. Baird upped their target price on shares of Tesaro from $105.00 to $120.00 and gave the stock an “outperform” rating in a report on Monday, October 10th. Wells Fargo & Co. reaffirmed an “outperform” rating on shares of Tesaro in a report on Thursday, June 30th. Finally, Zacks Investment Research raised shares of Tesaro from a “sell” rating to a “hold” rating in a report on Tuesday, July 5th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and thirteen have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $110.11.
Tesaro (NASDAQ:TSRO) traded down 0.95% on Friday, reaching $115.05. 728,969 shares of the company traded hands. Tesaro has a 1-year low of $29.51 and a 1-year high of $122.89. The stock has a 50 day moving average of $99.84 and a 200-day moving average of $71.24. The stock’s market capitalization is $5.91 billion.
Tesaro (NASDAQ:TSRO) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.28) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.71) by $0.43. The company had revenue of $36.60 million for the quarter, compared to the consensus estimate of $4.98 million. Tesaro had a negative net margin of 783.97% and a negative return on equity of 205.63%. During the same quarter last year, the firm posted ($1.51) EPS.
In other news, VP Edward C. English sold 7,000 shares of the stock in a transaction dated Thursday, September 8th. The shares were sold at an average price of $88.54, for a total transaction of $619,780.00. Following the sale, the vice president now owns 3,500 shares of the company’s stock, valued at $309,890. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Martin H. Jr. Huber sold 408 shares of the stock in a transaction dated Thursday, September 22nd. The stock was sold at an average price of $108.12, for a total transaction of $44,112.96. Following the sale, the senior vice president now directly owns 1,250 shares in the company, valued at approximately $135,150. The disclosure for this sale can be found here. 40.50% of the stock is currently owned by company insiders.
Hedge funds have recently modified their holdings of the company. CenturyLink Investment Management Co acquired a new stake in shares of Tesaro during the third quarter valued at about $172,000. KCG Holdings Inc. acquired a new stake in shares of Tesaro during the second quarter valued at about $228,000. Quantitative Systematic Strategies LLC acquired a new stake in shares of Tesaro during the second quarter valued at about $240,000. Bluestein R H & Co. acquired a new stake in shares of Tesaro during the second quarter valued at about $252,000. Finally, Neuberger Berman Group LLC acquired a new stake in shares of Tesaro during the second quarter valued at about $256,000. 88.81% of the stock is currently owned by institutional investors and hedge funds.
Tesaro Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.
Receive News & Ratings for Tesaro Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro Inc. and related companies with MarketBeat.com's FREE daily email newsletter.